Palmitoyl tripeptide-38

At a glance

Overview

This ingredient belongs to a family of lipid-modified cosmetic peptides, but its identity differs from original Matrixyl and the Matrixyl 3000 blend. The number in the ingredient name is part of the identifier, not a ranking of potency. The supplier promotes a matrix-related rationale involving multiple skin constituents. That claim should be assessed alongside the evidence design rather than treated as six independently demonstrated clinical benefits. Human research on a serum combining the peptide with antioxidants can be relevant to the final product, while still leaving the separate value of each component unresolved. The same distinction applies to brand-family comparisons.

Supporting sources [1] [2] [3]

How it works

The proposed mechanism involves signaling associated with extracellular-matrix and dermal-epidermal-junction components. Croda describes effects on six matrix-related constituents in its supplier material. Those laboratory or supplier observations are not equivalent to demonstrating that a consumer serum rebuilds all those structures in living skin. A formulation containing strong co-actives requires an appropriate component-control design to isolate any peptide-specific mechanism.

Supporting sources [1] [2] [3]

What the serum study found

A 2020 open-label study followed women using a serum containing ascorbic acid, tocopheryl acetate, and palmitoyl tripeptide-38 for 56 days. Instrumental roughness measurements and participant perceptions improved. Without a matched control and separate component comparisons, the study cannot determine how much change was due to the peptide, antioxidants, moisturizer vehicle, or expectation.

Supporting sources [1]

One brand family, different ingredients

The manufacturer lists palmitoyl tripeptide-38 in Matrixyl synthe’6. Original Matrixyl contains palmitoyl pentapeptide-4, while Matrixyl 3000 combines different peptides. Their studies should remain linked to the correct ingredient or blend; similar packaging or names do not make their molecular evidence interchangeable.

Supporting sources [2]

Cosmetic use is a bounded claim

Cosmetic status is not FDA drug approval. Short-term tolerability of an antioxidant serum does not establish injection safety or universal suitability of all formulations. Evidence should focus on the actual appearance endpoint and product tested, rather than converting matrix-related marketing language into a medical regeneration claim.

Supporting sources [1] [3]